These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12362492)

  • 1. [Clinical and economical advantages of anticoagulant treatment in specialized clinics].
    Goldberg Y; Berliner S; Seligsohn U
    Harefuah; 2002 Sep; 141(9):830-2, 856. PubMed ID: 12362492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ximelagatran: a new oral anticoagulant.
    Hrebickova L; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(6):397-408. PubMed ID: 14633322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study.
    Menzin J; Boulanger L; Hauch O; Friedman M; Marple CB; Wygant G; Hurley JS; Pezzella S; Kaatz S
    Ann Pharmacother; 2005 Mar; 39(3):446-51. PubMed ID: 15701783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective anticoagulation therapy: defining the gap between clinical studies and clinical practice.
    Wittkowsky AK
    Am J Manag Care; 2004 Oct; 10(10 Suppl):S297-306; discussion S312-7. PubMed ID: 15605700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of an open-label, prospective study of anticoagulant therapy for atrial fibrillation in an outpatient anticoagulation clinic.
    Abdelhafiz AH; Wheeldon NM
    Clin Ther; 2004 Sep; 26(9):1470-8. PubMed ID: 15531009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombotic therapies for stroke prevention in atrial fibrillation.
    Economides Muñoz C; Singh BN
    Minerva Cardioangiol; 2004 Apr; 52(2):125-39. PubMed ID: 15194994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New perspectives for anticoagulation in non-rheumatic atrial fibrillation: oral antithrombins].
    Scardi S; Giansante C
    Ital Heart J Suppl; 2004 Sep; 5(9):705-11. PubMed ID: 15568608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen.
    Douketis JD; Johnson JA; Turpie AG
    Arch Intern Med; 2004 Jun; 164(12):1319-26. PubMed ID: 15226166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation.
    Leey JA; McCabe S; Koch JA; Miles TP
    Am J Geriatr Pharmacother; 2009 Aug; 7(4):197-203. PubMed ID: 19766951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of pharmacist-managed oral anticoagulation therapy in older veterans.
    Poon IO; Lal L; Brown EN; Braun UK
    J Clin Pharm Ther; 2007 Feb; 32(1):21-9. PubMed ID: 17286786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thromboembolic prophylaxis in nonrheumatic atrial fibrillation: utilization patterns, efficacy, and complications in a long-term follow-up of community patients.
    Blich M; Gross B
    Int J Cardiol; 2004 Jul; 96(1):89-95. PubMed ID: 15203266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of anticoagulation monitoring in nonvalvular atrial fibrillation patients: comparison of anticoagulation clinic versus usual care.
    Nichol MB; Knight TK; Dow T; Wygant G; Borok G; Hauch O; O'Connor R
    Ann Pharmacother; 2008 Jan; 42(1):62-70. PubMed ID: 18094348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? A cost-utility analysis.
    Quinn RR; Naimark DM; Oliver MJ; Bayoumi AM
    Am J Kidney Dis; 2007 Sep; 50(3):421-32. PubMed ID: 17720521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulant treatment of patients with chronic atrial fibrillation in primary health care in Sweden--a retrospective study of incidence and quality in a registered population.
    Nilsson GH; Björholt I; Krakau I
    Fam Pract; 2004 Dec; 21(6):612-6. PubMed ID: 15465879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Periprocedural management of anticoagulation in patients on extended warfarin therapy.
    Jafri SM; Mehta TP
    Semin Thromb Hemost; 2004 Dec; 30(6):657-64. PubMed ID: 15630672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation.
    Halperin JL
    J Am Coll Cardiol; 2005 Jan; 45(1):1-9. PubMed ID: 15629364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Warfarin exposure and the risk of thromboembolic and major bleeding events among medicaid patients with atrial fibrillation.
    Boulanger L; Hauch O; Friedman M; Foster T; Dixon D; Wygant G; Menzin J
    Ann Pharmacother; 2006 Jun; 40(6):1024-9. PubMed ID: 16735649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: the low INR study.
    Clark NP; Witt DM; Delate T; Trapp M; Garcia D; Ageno W; Hylek EM; Crowther MA;
    Pharmacotherapy; 2008 Aug; 28(8):960-7. PubMed ID: 18657012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atrial fibrillation and anticoagulation.
    Garnier LF; Rouesnel P; Espitalier F
    Arch Mal Coeur Vaiss; 2004 Oct; 97(10):1001-5. PubMed ID: 16008178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Selçuk H; Selçuk MT; Maden O
    Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.